Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Chronic Spontaneous Urticaria (SUNRISE)
NCT02550106Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Apr 2015; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT02550106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550106.